114 related articles for article (PubMed ID: 32530777)
1. Vastus lateralis myocutaneous flap for ischial skin wound following the treatment of epithelioid sarcoma using pazopanib.
Tsujii M; Matsumine A; Nakamura T; Satonaka H; Sudo A
J Wound Care; 2020 Jun; 29(6):335-339. PubMed ID: 32530777
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
[TBL] [Abstract][Full Text] [Related]
3. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
[TBL] [Abstract][Full Text] [Related]
5. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Haas RL; Gelderblom H; Sleijfer S; van Boven HH; Scholten A; Dewit L; Borst G; van der Hage J; Kerst JM; Nout RA; Hartgrink HH; de Pree I; Verhoef C; Steeghs N; van Coevorden F
Acta Oncol; 2015; 54(8):1195-201. PubMed ID: 25920360
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS
BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622
[TBL] [Abstract][Full Text] [Related]
7. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai H; Fukasawa N; Ueta F
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
[No Abstract] [Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
[TBL] [Abstract][Full Text] [Related]
12. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
13. Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.
Vlenterie M; Oyen WJ; Steeghs N; Desar IME; Verheijen RB; Koenen AM; Grootjans W; DE Geus-Oei LF; VAN Erp NP; VAN DER Graaf WT
Anticancer Res; 2019 Mar; 39(3):1309-1316. PubMed ID: 30842163
[TBL] [Abstract][Full Text] [Related]
14. The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib.
Mori Y; Kinoshita S; Kanamori T; Kataoka H; Joh T; Iida S; Takemoto M; Kondo M; Kuroda J; Komatsu H
Intern Med; 2018 Sep; 57(18):2753-2757. PubMed ID: 29780156
[TBL] [Abstract][Full Text] [Related]
15. Reconstruction of complex soft-tissue defects around the knee joint with distally based split vastus lateralis musculocutaneous flap: a new technique.
Sahasrabudhe P; Panse N; Baheti B; Jadhav A; Joshi N; Chandanwale A
J Plast Reconstr Aesthet Surg; 2015 Jan; 68(1):35-9. PubMed ID: 25448368
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04).
Ronellenfitsch U; Karampinis I; Dimitrakopoulou-Strauss A; Sachpekidis C; Jakob J; Kasper B; Nowak K; Pilz L; Attenberger U; Gaiser T; Derigs HG; Schwarzbach M; Hohenberger P
Ann Surg Oncol; 2019 May; 26(5):1332-1339. PubMed ID: 30843160
[TBL] [Abstract][Full Text] [Related]
17. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Deng Y; Sychterz C; Suttle AB; Dar MM; Bershas D; Negash K; Qian Y; Chen EP; Gorycki PD; Ho MY
Xenobiotica; 2013 May; 43(5):443-53. PubMed ID: 23548165
[TBL] [Abstract][Full Text] [Related]
19. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).
Ronellenfitsch U; Dimitrakopoulou-Strauss A; Jakob J; Kasper B; Nowak K; Pilz LR; Attenberger U; Gaiser T; Egerer G; Fröhling S; Derigs HG; Schwarzbach M; Hohenberger P
BMJ Open; 2016 Jan; 6(1):e009558. PubMed ID: 26739732
[TBL] [Abstract][Full Text] [Related]
20. Nursing considerations for patients with sarcoma on pazopanib therapy.
Holland J; Flaherty C
Clin J Oncol Nurs; 2015 Jun; 19(3):E59-62. PubMed ID: 26000592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
